StephenSFlitmanMD

Clinical Trials

• Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo Start of enrollment: 2013 Jul 01

  Terminated

  Phase 3

• A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes Start of enrollment: 2017 Apr 01

  Withdrawn

  Phase 3

• 18F-AV-1451 Autopsy Study Start of enrollment: 2015 Sep 01

  Completed

  Phase 3

• Fixed-Dose Trial in Early Parkinson's Disease (PD) Start of enrollment: 2019 Dec 13

  Active, not recruiting

  Phase 3

  Roles: Contact

• Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations Start of enrollment: 2020 Oct 27

  Completed

  Phase 3

  Roles: Contact

• Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease Start of enrollment: 2021 Nov 03

  Active, not recruiting

  Phase 3

  Roles: Contact, Principal Investigator

• A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease. Start of enrollment: 2018 Oct 10

  Completed

  Phase 2

  Roles: Contact, Principal Investigator

• Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects Start of enrollment: 2024 Apr 02

  Enrolling by invitation

  Phase 3

  Roles: Principal Investigator, Contact

• Join now to see all